ERBB2 and breast carcinoma: A part of the findings was presented at San Antonio Breast Cancer Symposium 2022 under the title ‘Neoadjuvant hormonal therapy plus palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer’ (38).